Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for
Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Of The Most Ridiculously Undervalued Dividend Stocks On My Radar
The market's rally is all Big Tech and hype, but beneath the surface, breadth is weak and valuations are stretched. This isn't a great setup for index investors. Fortunately, this is still a market of stocks. Bottom-up targets show real value in sectors like energy, healthcare, and real estate. That's why I'm zooming in on two dirt-cheap dividend plays, under-the-radar names with strong fundamentals and serious long-term upside.
Boise Cascade (BCC) Up 0.1% Since Last Earnings Report: Can It Continue?
Boise Cascade (BCC) reported earnings 30 days ago. What's next for the stock?
New Strong Sell Stocks for May 28th
BCC, DOOO and CMT have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2025.
Boise Cascade Company (BCC) Q1 2025 Earnings Call Transcript
Boise Cascade Company (NYSE:BCC ) Q1 2025 Earnings Conference Call May 6, 2025 9:30 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Joanna Barney - EVP, Building Materials Distribution Conference Call Participants Susan Maklari - Goldman Sachs Kurt Yinger - D.A. Davidson George Staphos - Bank of America Securities Zack Pacheco - Loop Capital Markets Ketan Mamtora - BMO Capital Markets Reuben Garner - Benchmark Operator Good morning.
Boise Cascade Q1 Earnings Miss Estimates, Sales Beat, Stock Dips
BCC's first-quarter 2025 results reflect lower volumes and unfavorable sales price trends across product categories.
Boise Cascade (BCC) Lags Q1 Earnings Estimates
Boise Cascade (BCC) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $2.61 per share a year ago.
Boise Cascade Reports Lower Sales, Profit as Home Construction Slows
The maker of wood products said the 2025 market demands are difficult to predict, with most forecasts for housing starts ranging from flat to mid-single-digit declines, year-over-year.
Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for
Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boise Cascade: Priced For A Recession, But Built To Survive It
Boise Cascade, a leading wood products' manufacturer, is rated a Buy due to its strong balance sheet and long-term housing market tailwinds, despite short-term cyclical challenges. The company benefits from vertical integration, sourcing raw timber cost-effectively, and distributing finished lumber products to major retailers and builders. BCC's financial health is robust, with a low debt/equity ratio and significant cash reserves, positioning it well to weather economic downturns.
Buying A Dollar For 60 Cents: 2 Dividend Stocks With Potential Upside
The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies with strong fundamentals. I focus on businesses with resilient models, growth potential, and attractive valuations. Despite headline risks, I believe in their ability to navigate uncertainty and deliver long-term returns. While risks like prolonged trade tensions or economic slowdowns exist, I remain confident in my picks, as they are well-positioned to thrive regardless of short-term market turbulence.
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
